Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).
The emerging sciences of stem cell biology and cellular plasticity have led to the development of cell-based therapies for advanced human disease. Pre-clinical studies which defined the potential of bone marrow-derived mononuclear cells to repair damaged and dysfunctional myocardium led to the rapid advancement of these strategies to the clinic. Such rapid advancement has led to controversy regarding the appropriate conduct of such studies. In the United States, the National Heart, Lung, and Blood Institute established the Cardiovascular Cell Therapy Research Network (CCTRN) to facilitate the early translation of clinical trials of cell therapy for left ventricular dysfunction. The premise upon which the CCTRN was established was that multiple clinical trial sites would interact effectively with a Data Coordinating Center to perform early phase 1 and 2 clinical trials within a highly coordinated network structure. In order to develop this network, the unmet needs of the community needed to be defined, the clinical trials identified, and the structure to perform the studies needed to be established. This manuscript highlights the challenges in the development of the CCTRN and the approaches faced to define a network to perform clinical trials in human cell therapy of cardiovascular disease.
Simari
Robert D
RD
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Moyé
Lemuel A
LA
Skarlatos
Sonia I
SI
Ellis
Stephen G
SG
Zhao
David X M
DX
Willerson
James T
JT
Henry
Timothy D
TD
Pepine
Carl J
CJ
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003299:Cooperative Behavior; D019317:Evidence-Based Medicine; D006801:Humans; D007373:Interinstitutional Relations; D015337:Multicenter Studies as Topic; D054555:National Heart, Lung, and Blood Institute (U.S.) / Q000458:organization & administration*; D009937:Organizational Objectives; D017410:Practice Guidelines as Topic; D016730:Program Development; D020127:Recovery of Function; D012107:Research Design; D033581:Stem Cell Transplantation; D057170:Translational Research, Biomedical / Q000458:organization & administration*; D016896:Treatment Outcome; D014481:United States; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology / Q000601:surgery*; D016277:Ventricular Function, Left
J Allergy Clin Immunol. 2007 Jan;119(1):3-11; quiz 12-3
17141853
Nature. 2004 Apr 8;428(6983):668-73
15034594
Circulation. 2002 Dec 10;106(24):3009-17
12473544
Nat Med. 2001 Apr;7(4):430-6
11283669
Lancet. 2004 Jul 10-16;364(9429):141-8
15246726
N Engl J Med. 2001 Jun 7;344(23):1750-7
11396441
Am Heart J. 2009 Sep;158(3):356-63
19699857
Lancet. 2006 Jan 14;367(9505):113-21
16413875
N Engl J Med. 2006 Sep 21;355(12):1199-209
16990383
Clin Pharmacol Ther. 2007 Sep;82(3):334-6
17625516
Nature. 2004 Apr 8;428(6983):664-8
15034593
Control Clin Trials. 2001 Dec;22(6 Suppl):126S-34S
11728619
J Clin Invest. 2001 Jun;107(11):1395-402
11390421
Clin Pharmacol Ther. 2008 Nov;84(5):620-3
18701884
Nature. 2001 Apr 5;410(6829):701-5
11287958
Blood. 2004 Jan 1;103(1):133-5
12969964
Coron Artery Dis. 2009 Mar;20(2):106-11
19225399
Cytotherapy. 2008;10(2):203-11
18368599
Arch Intern Med. 2007 May 28;167(10):989-97
17533201
Clin Pharmacol Ther. 2009 May;85(5):548-52
19212313
Control Clin Trials. 2001 Dec;22(6 Suppl):119S-25S
11728618
N Engl J Med. 2006 Sep 21;355(12):1210-21
16990384
N Engl J Med. 2006 Sep 21;355(12):1222-32
16990385